VistaGen Therapeutics Inc. announced appointment of Michael Liebowitz, M.D. to the its CNS Clinical and Regulatory Advisory Board in preparation for pivotal Phase 3 development of PH94B as the first rapid-acting, on-demand treatment for social anxiety disorder (SAD), a debilitating social phobia which affects as many as 15 million American adults. He is also Managing Director of The Medical Research Network LLC and serves on the editorial board of Depression and Anxiety.Dr. Liebowitz has published numerous journal articles, books and chapters about psychiatry.